Novartis CEO expects tariff protection for US products by mid-2026 through domestic manufacturing
Novartis AG expects to mitigate US tariff exposure by mid-2026 through domestic production. This follows a $23 billion investment and a government agreement.
Insights:
Novartis AG CEO Vas Narasimhan vas narasimhanannounced on Tuesday, January 20, 2026, that the pharmaceutical company expects to achieve protection from potential trade tariffs by mid-2026. This objective will be met through the expansion of manufacturing capacity within the US 
USand an existing agreement with the federal government. The strategy focuses on producing medications domestically for the American market to ensure the company is not exposed to import levies.
USand an existing agreement with the federal government. The strategy focuses on producing medications domestically for the American market to ensure the company is not exposed to import levies.Novartis AGis a Swiss 
CHpharmaceutical company with significant operations in the US. The firm is currently progressing multiple manufacturing projects intended to reduce its vulnerability to trade policy changes. Vas Narasimhanclarified that by the middle of 2026, the firm expects to reach a position where its domestic production for the USmarket effectively eliminates tariff exposure.
CHpharmaceutical company with significant operations in the US. The firm is currently progressing multiple manufacturing projects intended to reduce its vulnerability to trade policy changes. Vas Narasimhanclarified that by the middle of 2026, the firm expects to reach a position where its domestic production for the USmarket effectively eliminates tariff exposure.
